Recent genetic investigations have established that RhoB gain-of-function is sufficient to mediate the antitransforming effects of farnesyltransferase inhibitors (FTIs) in H-Ras-transformed fibroblast systems. In this study, we addressed the breadth and mechanism of RhoB action in epithelial cells transformed by oncoproteins which are themselves insensitive to FTI inactivation. Rat intestinal epithelial (RIE) cells transformed by activated K-Ras or Rac1 were highly sensitive to FTI-induced actin reorganization and growth inhibition, despite the inability of FTI to block prenylation of either K-Ras or Rac1. Ectopic expression of the geranylgeranylated RhoB isoform elicited in cells by FTI treatment phenocopied these effects. Analysis of RhoB effector domain mutants pointed to a role for PRK, a Rho effector kinase implicated in the physiological function of RhoB in intracellular receptor trafficking, and these findings were supported further by experiments in a fibroblast system. We propose that FTIs recruit the antioncogenic RhoB protein in the guise of RhoB-GG to interfere with signaling by pro-oncogenic Rho proteins, possibly by sequestering common exchange factors or effectors such as PRK that are important for cell transformation.
Introduction
Farnesyltransferase inhibitors (FTIs) are a class of signal transduction inhibitors in cancer clinical trials that are providing a useful new tool to study neoplastic pathophysiology. FTIs were designed to attack Ras oncoproteins, the function of which depends on posttranslational modification by farnesyl isoprenoid. However, it has become increasingly clear and accepted that the drugs' antineoplastic properties can be traced to a large degree to an alteration in the prenylation and function of proteins other than Ras (Rowinsky et al., 1999; Sebti and Hamilton, 2000; Prendergast and Oliff, 2000; Prendergast, 2000a Prendergast, , 2001 Adjei, 2001; Cox, 2001) . One candidate target that has emerged from studies of the cellular response to FTI is RhoB. Investigations of this endosomal Rho protein have revealed an antioncogenic function that is recruited in cells by FTI through a gain-of-function mechanism (Prendergast, 2000a (Prendergast, , 2001 . Genetic investigations have established that RhoB is sufficient and/or necessary to mediate many facets of the FTI response displayed in mouse and rodent model systems or in human cancer cells (Du et al., 1999a; Du and Prendergast, 1999; . These findings have been extended recently by the identification of RhoB as a negative modifier function in cancer cells, which is required for the antineoplastic response to DNA damaging agents and paclitaxel (Liu et al., 2001a, b) . Thus, the use of FTIs to probe neoplastic pathophysiology has yielded two new concepts: the concept that Rho signaling affects chemotherapeutic responses, and the concept that cancer chemotherapeutics must recruit negative modifier functions to effectively target neoplastic cells.
Important remaining issues regarding RhoB in the FTI response include the following. First, the main evidence for this link has been obtained in cells transformed by H-Ras, which is a relatively less important human oncogene than K-Ras. Is RhoB involved in the FTI response in K-ras-transformed cells? This question bears on the long-standing issue of how FTI manages to suppress K-ras transformation without blocking K-ras prenylation (because of the ability of geranylgeranyltransferase-I (GGT-I) to prenylate and maintain the function of K-ras in FTI-treated cells (Lerner et al., 1997; Rowell et al., 1997; Whyte et al., 1997) . Second, what effector signaling pathways does RhoB use to mediate its antiproliferative effects in transformed cells? Work from Mellor and colleagues has defined a function for RhoB in intracellular receptor trafficking (Gampel et al., 1999) , which depends on interactions with the Rho effector kinase PRK (Mellor et al., 1998; Flynn et al., 2000) , but it is not known whether this pathway is involved in the antiproliferative actions of RhoB in transformed cells. This question also bears on the relation between RhoB and its prooncogenic relatives, the RhoA and RhoC proteins, which can also interact with PRK as well as other Rho effector proteins (because of the identical effector domains on the RhoA/B/C proteins). Pro-oncogenic Rho signals are required for transformation by Ras (Khosravi-Far et al., 1995; Qiu et al., 1995) . Marshall and colleagues have proposed that this requirement is based on the negation of cell cycle kinase inhibitors (CDKIs) that are induced by oncogenic Ras (Olson et al., 1998) . Because of the identity of the effector domains in the RhoA/B/C proteins, the simplest way to interpret the antagonistic effects of RhoB on transformation is to propose that it antagonizes signaling from the pro-oncogenic RhoA/C proteins (Prendergast, 2001) , perhaps by sequestering common Rho effector molecules such as PRK kinases. A strong prediction of this model is that FTI should block transformation by pro-oncogenic Rho proteins that are geranylgeranylated. Work in this study and elsewhere (van Golen et al., 2002) offers evidence to support this model, which suggests new insights into RhoB function and into its role in the response to FTI and other chemotherapeutics.
Materials and methods

Cell culture
Rat Intestinal Epithelial (RIE) cells were cultured in Dulbecco's modified Eagle medium (DMEM; Life technologies) supplemented with 5% fetal bovine serum (FBS; Hyclone) and antibiotics. Mouse embryo fibroblasts and Rat1/ras cells (Kohl et al., 1993) were cultured in the same media except being supplemented with 10% FBS. RIE cells were transformed with an activated K-Ras-4B(G12V) cDNA expressed from a neo-tagged pZIP retroviral vector or with an activated Rac1(Q61L) cDNA expressed from a neo-tagged pcDNA3 vector (Invitrogen). Cells were passaged 48 h after transfection in media containing 500 mg/ml G418 and transformed colonies were ring cloned and expanded as clonal cell lines. Transgene expression in transformed cell lines was confirmed by Western analysis. Multiple clones tested for FTI responsiveness yielded highly similar results; representative data from a single randomly chosen K-Ras or Rac1 clone are presented in the study. RIE/K-ras or RIE/Rac1 derivatives that expressed RhoB-GG or RhoB-GG effector mutants were generated by infection with recombinant retroviruses. For these experiments, a hemagglutinin antigen epitope (HA)-tagged RhoB-GG cDNA that had been described previously (Du et al., 1999a ) was used as a target for mutagenesis and subcloned into the replication-incompetent retroviral vector MSCVpac, which includes a puromycin selection marker (Hawley et al., 1994) . Effector mutants were generated in the HA-RhoB-GG cDNA using the QuikChanget mutagenesis kit (Strategene) according to the vendor's protocol and verified by DNA sequencing (oligonucleotide sequences used for plasmid construction are available upon request). Recombinant MSCVpac viruses were packaged by standard methods in Phoenix cells. After infection, cells were passaged in to DMEM media containing 1-4 mg/ml puromycin and drugresistant cell populations were pooled for analysis. Rat1/ras cells were transfected with epitope-tagged wild-type or kinasedead PRK2 expression vectors or with the pcDNA3 vector alone using the commercial CalPhos mammalian transfection kit, using the vendor's instructions (Clontech). Cells were passaged 48 h after transfection in media containing 100 mg/ml zeocin, ring cloned, and expanded as cell lines. Transgene expression was confirmed in cell populations by Western analysis.
Western analysis
Cell extracts prepared in NP40 lysis buffer were analysed by standard methods using a commercial chemiluminescence kit to develop Western blots (Pierce). K-RasV12 was detected with sc-30 mouse monoclonal antibody, Rac1 was detected with sc-217 rabbit antisera, and endogenous RhoB was detected with sc-180 rabbit antisera (Santa Cruz Biochemicals); HA-tagged RhoB transgene was detected with anti-HA mouse monoclonal antibody 12CA5 (Roche Biochemicals); PRK2 was detected with anti-PRK2 antibody (Transduction Laboratories); myc epitope-tagged kinase-dead PRK2 was detected with anti-myc monoclonal antibody 9E10; V5 epitope-tagged PRK2 transgene was detected using an anti-V5 antibody (Invitrogen).
Cell morphology
Cells were seeded in a 10 cm tissue culture dish and photographed 24 h later at Â 100 magnification under the conditions noted. In FTI experiments, dimethyl sulfoxide (DMSO) was added as vehicle in control trials to no more than 0.1% (v/v) of the culture media.
Cell proliferation and viability assays
Anchorage-dependent cell growth in monolayer cultures was measured by MTT (3-(4,5-dimethylthiazoly-2-yl)2,5-diphenyltetrazolium bromide) assay (Roche) according to the manufacturer's protocol. Briefly, cells were seeded at 2000 cells per well in 96-well culture plates in quadruplicate. At appropriate times, 0.5 mg/ml MTT was added to each well and the 96-titer plate was incubated at 371C in a humidified incubator in which 5% CO 2 was maintained. After 4 h 100 ml of solubilization buffer (10% SDS in 0.01 m HCl) was added to each well and incubated overnight in a humidified atmosphere before quantification. To monitor anchorage-independent cell proliferation, colony formation assays in soft agar culture were performed as described previously (Du et al., 1999a) . Apoptosis was quantitated by flow cytometry using standard methods that have been described previously (Liu et al., , 2001a . The proportion of apoptotic cells in a population was defined as the proportion of cells exhibiting sub-G1 phase DNA.
Actin immunofluroscence
Cells were seeded onto coverslips in six-well dishes and treated 24 h with 10 mm FTI or an equivalent volume of vehicle. Cells were fixed and stained with fluorescein-phalloidin (Molecular Probes) and photographed using indirect immunofluorescence microscopy as described previously (Prendergast et al., 1994) .
Transcription assay
A derivative of the SRE reporter construct 3D.ACAT that employs luciferase instead of chloramphenicol acetyl transferase as the reporter gene (Liao et al., 1997) was used to probe the effects of various RhoB effector mutations on SRE activation. Transcription assays were performed similarly as described except using FuGene 6 reagent (Roche Biochemicals) in rhoBÀ/À mouse embryo fibroblasts .
The b-galactosidase reporter plasmid CMVÀb gal was used to normalize for transfection efficiency (Lebowitz et al., 1997b) .
Results
Intestinal epithelial cells transformed by K-Ras or Rac1 are highly susceptible to FTI treatment: association with elevation of RhoB-GG RIE/K-ras cells were generated by transformation with the activated K-Ras mutant K-Ras4B-G12V. The response of these cells to farnesyltransferase inhibition was studied using the FTI L-744,832, a highly potent and specific compound that does not block the activity of cellular geranylgeranyltransferases (Kohl et al., 1995) . Control experiments to examine the effects of FTI on untransformed RIE cells employed the matched vector cell line RIE/neo. FTI treatment rapidly elicited an elevation in the levels of the geranylgeranylated isoform of RhoB that is synthesized in drug-treated cells (RhoB-GG), consistent with previous observations (Lebowitz et al., 1997a) . RhoB-GG induction was more pronounced in RIE/K-ras cells, but in both cell lines its elevation was detectable as early as 4 h after drug treatment, preceding any apparent cellular response ( Figure 1a ). Within 12-16 h a dramatic shift in the morphology of drug-treated RIE/K-Ras cells became apparent ( Figure 1b) . The flattened and enlarged morphology observed was highly reminiscent of the phenotypic reversion displayed in H-Ras-transformed fibroblasts, and unexpectedly, owing to the reported 'resistance' of K-Ras-transformed fibroblasts to FTI treatment, within the same dose range. While less dramatic, the morphology of untransformed RIE/neo cells was altered similarly with the same kinetics and dose range (Figure 1b ). Following work in fibroblast systems, which links phenotypic reversion to a RhoBdependent reorganization of the actin cytoskeleton (Du et al., 1999a; , we examined the organization of F-actin in drug-treated RIE cells. As expected, K-Ras transformation was associated with a complete disruption of the stress fiber network that characterized untransformed RIE cells (Figure 1c) . Similar to what is seen in fibroblast models (Prendergast et al., 1994) , the morphological shift produced by FTI was associated with the reinstatement of a stress fiber network in RIE/K-ras cells and with the stimulation of a more robust stress fiber network in RIE/neo cells. RhoB-GG is sufficient and necessary to mediate FTIinduced actin reorganization in H-Ras-transformed fibroblasts (Du et al., 1999a; ; the induction of RhoB-GG by FTI in RIE cells was consistent with a similar role here.
The proliferation of RIE/K-ras cells was also highly sensitive to disruption by FTI treatment, despite the noted inability of FTI to block K-Ras prenylation and therefore function. The proliferation of RIE/K-ras cells in monolayer culture was virtually halted by FTI treatment (Figure 2a ). The IC 50 for this effect was indistinguishable from that required to block the proliferation of H-Ras-transformed fibroblasts (data not shown). By comparison, the division of RIE/neo cells was slowed, but not stopped, consistent with previous demonstrations that FTIs more effectively target the growth of transformed cells. Under anchorage-independent conditions, where RIE/K-ras, but not RIE/neo, cells were capable of cell division, a similar sensitivity of RIE/K-ras cells to growth suppression by FTI treatment was demonstrated (Figure 2b ). Consistent with observations in K-Ras-transformed NRK fibroblasts (Suzuki et al., 1998) , RIE/K-ras cells were susceptible to FTI-induced apoptosis under low growth Cells seeded onto coverslips were treated as above, fixed, and processed for F-actin staining using FITC-conjugated phalloidin factor conditions (data not shown). The dose required to suppress colony formation or induce apoptosis under these different conditions (1-5 mm L-744,832) was in the same range as that determined in assays using H-Rastransformed fibroblasts. These observations also contrasted with the reported 'resistance' of K-Rastransformed fibroblasts to FTI treatment. We concluded that, despite the well-documented inability of FTI to block K-Ras prenylation, because of its alternate geranylgeranylation in FTI-treated cells (Lerner et al., 1997; Rowell et al., 1997; Whyte et al., 1997) , RIE/K-ras cells were fully susceptible to the antitransforming effects of FTI treatment.
To explicitly test whether FTI could bypass a geranylgeranylated oncoprotein to suppress cell transformation, we investigated the response of Rac1-transformed cells to FTI treatment. Rac1 is solely geranylgeranylated in cells, so FTI L-744,832 cannot affect the function of this oncoprotein. The activated mutant Rac1-Q61L was used to generate transformed RIE/rac1 cells. As before, FTI treatment rapidly elicited an elevation in the cellular levels of RhoB-GG within 4 h of drug treatment, preceding any apparent cellular response (Figure 3a) . The phenotype of RIE/rac1 cells was comparatively flat, relative to RIE/neo control cells, but pronounced membrane ruffles were apparent that gave the cells a hard-edged appearance. Within 12-16 h of drug treatment, a shift in the morphological phenotype could be seen, with a loss of the pronounced membrane ruffles and a subtle flattening of cell shape (Figure 3b ). F-actin staining revealed the presence of both ruffles (blurred in the figure) and stress fibers in untreated RIE/rac1 cells (Figure 3c ). More pronounced pseudopods were also apparent. Interestingly, FTI treatment diminished the ruffles and pseudopods but had little overt effect on stress fiber organization (Figure 3c ). The proliferation of RIE/rac1 cells in monolayer culture was suppressed by FTI treatment, but under these conditions not as robust as produced in RIE/K-ras cells (Figure 3d ). However, under anchorageindependent conditions, growth suppression was more robust and comparable to that seen in RIE/K-ras cells ( Figure 3e ). As before, the antiproliferative effects were achieved at dose ranges that were comparable to those required to block the anchorage-independent growth of H-Ras-transformed fibroblasts. We were unable to perform the apoptosis experiment, because RIE/rac1 cells underwent apoptosis when deprived of serum growth factors alone (data not shown). Nevertheless, these observations indicated that RIE1/rac1 cells were susceptible to the antitransforming effects of FTI, despite its inability to block the geranylgeranylation and therefore the function of the Rac1 oncoprotein. We concluded that FTI could bypass geranylgeranylated 'driver' oncoproteins to elicit reversion and suppress proliferation in transformed cells.
RhoB-GG phenocopies the actin reorganization and growth suppression produced by farnesyltransferase inhibition in transformed intestinal epithelial cells
In H-Ras-transformed fibroblast model systems, the RhoB-GG elicited by FTI is sufficient and necessary to mediate actin reorganization and sufficient to suppress proliferation (Du et al., 1999a; . The ability of FTI to elicit RhoB-GG in RIE cells prompted us to confirm whether ectopic RhoB-GG was sufficient to phenocopy the FTI response in these cells. RIE/K-ras or RIE/neo cell populations that stably expressed RhoB-GG or vector sequences were generated by infection with recombinant retroviruses (Figure 4a ). RhoB-GG expression caused a slight flattening of RIE/ neo cells, increasing their size to a degree similar to FTI treatment (Figure 4b, top panels) . RhoB-GG also caused a flattening of RIE/K-ras cells, but only to a partial extent that did not fully mimic the effects of FTI treatment (Figure 4b, bottom panels) . The partial effect seen might reflect a dose response; FTI induces endogenous RhoB-GG to much higher levels in RIE/Kras cells than RIE/neo cells (Figure 1a) , so the dose of ectopic RhoB-GG might reach the dose needed to induce the full morphological shift in RIE/neo cells, but not in RIE/K-ras cells. Alternately, RhoB-GG might not be sufficient to phenocopy the morphological shift fully. The latter interpretation is perhaps more appealing, insofar as ectopic RhoB-GG could phenocopy the actin stress fiber induction to a more similar extent in both RIE/neo and RIE/K-ras cells (Figure 4c ). This result argues that the induction of endogenous RhoB-GG by FTI is sufficient to mediate actin reorganization. Ectopic RhoB-GG also effectively phenocopied the growth suppression of RIE/K-ras cells by FTI, both in monolayer culture (data not shown) and under anchorage-independent conditions (Figure 4d ). Similar antiproliferative effects of RhoB-GG were observed under the same conditions in RIE/rac1 cells (data not shown).
We concluded that the induction of RhoB-GG by FTI was a sufficient cause to mediate actin stress fiber formation and growth inhibition.
Evidence of a role for the RhoB effector kinase PRK in the antiproliferative effects of farnesyltransferase inhibition in transformed cells
The results above suggest that RhoB-GG indirectly interferes with cell transformation by K-Ras or Rac1, consistent with other evidence that RhoB has antioncogenic role in cells (Liu et al., 2001a, b) . To probe the basis for its activity, we investigated the effect of various effector domain mutations in RhoB-GG. RhoB is B90% identical to RhoA in its primary structure and, in particular, the effector domains of these small GTPases are identical. Thus, effector molecules that have been defined through interaction with RhoA have in every case tested also interacted with RhoB, as would be expected on the basis of structural considerations. In a retroviral vector, we introduced into RhoB-GG six different effector domain mutations that have been shown in RhoA to affect interactions with various Rho effector molecules to variable degrees (Table 1) . RIE/K-ras cell populations that expressed these mutant derivatives were then examined in the assays for actin organization and anchorage-independent growth used above. Since the response of cells to FTI and RhoB is influenced by serum growth factors , we also tested the effector mutants for their ability to activate transcription of the serum response element (SRE), a transcriptional target of RhoB (Lebowitz et al., 1997b) . The results of these experiments are summarized in Table 1 and shown in Figures 5 and 6 .
The set of effector domain mutants tested discriminated between possible mechanisms of growth suppression and SRE activation, but not actin reorganization. All the effector mutants were able to induce actin stress fibers to a considerable degree in RIE/K-ras cells (Figure 5a ). These observations included the T37Y mutant that binds weakly to most Rho effector molecules (Sahai et al., 1998) . This result argued that interactions with several different effectors could trigger actin reorganization, any one of which may be sufficient. In contrast to this result, two mutants clearly discriminated interactions with the Rho effector kinase PRK as important for suppression of anchorage-dependent growth and SRE activation (Figure 5b and Figure 6 ). The patterns of activity for F39L and E40T, mutants which retained the ability to bind PRK, linked productive interactions with RhoB-GG to its ability to -GG  ++  ++  ++  ++  ++  ++  ++  ++  ++  ++  T37Y  ++  -----+/À  ---F39A  ++  -------++  -F39L  +  ++  ++  +  +  +  --++  +  F39V  ++  ---++  ---++  ++  E40T  ++  +  ++  +  ++  ++  -++  ++  +  Y42C ++ ---++ + + ++ ++ + Figure 5 Effects of effector domain mutations on growth suppression and actin organization by RhoB-GG. (a) RIE/K-ras cell populations that were derived from infections with retroviral vectors expressing no insert (vector), RhoB-GG, or the RhoB-GG effector domain mutants indicated were seeded into soft agar culture. Colony formation was documented by photomicrography 12 days after seeding. (b) The same RIE/K-ras cell populations derived above were seeded onto coverslips and processed the next day for actin staining with FITC-conjugated phalloidin as before suppress proliferation and activate transcription (Table 1) . This connection was satisfying, insofar as the results were highly consistent with the evidence that PRK interaction is crucial for the physiological function of RhoB in the intracellular trafficking of the EGF receptor and perhaps other receptors (Mellor et al., 1998; Gampel et al., 1999) . To further probe the relation of PRK to the FTI response, we expressed it in Rat1/ras fibroblasts, an HRas-transformed cell system that has been widely used for FTI studies (Kohl et al., 1993; Prendergast et al., 1994; Lebowitz et al., 1995 Lebowitz et al., , 1997c Du et al., 1999a ,b) . For these experiments, we used PRK2 since this PRK isoform is expressed in Rat1/ras cells; both PRK1 and PRK2 are recruited similarly by RhoB to endosomal vesicles (Mellor et al., 1998; Gampel et al., 1999) (H Mellor, pers. comm.) . To probe possible effects of the PRK kinase domain or membrane recruitment, we also expressed a kinase-dead mutant (PRK2-KD) or an Nmyristoylated derivative of PRK2 in Rat1/ras cells. Several clones analysed for each Rat1/ras derivative acted similarly; results from representative clones are presented here (Figure 7a) . Interestingly, ectopic PRK2 relieved the requirement for serum deprival for FTI to induce apoptosis in Rat1/ras cells. Under control conditions (i.e. monolayer culture in media containing 10% FBS), FTI treatment induces reversion and growth inhibition in Rat1/ras fibroblasts, whereas if serum growth factors are deprived, FTI treatment triggers an apoptotic program (Du et al., 1999c) . In contrast to vector control cells, which acted like the parental cells, PRK2-expressing cells underwent apoptosis in serumcontaining media as evidenced in phase micrographs or flow cytometry (Figure 7b,c) . The kinase activity of PRK2 was implicated, because cells expressing the kinase-dead PRK-KD mutant did not recapitulate the effect, instead retaining the requirement of serum deprivation for FTI-induced apoptosis. Myr-PRK2-expressing cells were resistant to FTI-induced apoptosis. Myristylation relieves the requirement for Rho to mediate membrane recruitment. Therefore, the ability of myr-PRK2 to block apoptosis suggested that the proapoptotic effects of PRK2 in the FTI response were linked not only to its kinase activity, but also to its localization and/or movement in cells. This observation was notable in light of the evidence that FTI alters the localization as well as the level of RhoB-GG in cells, and that both changes might be needed for the FTI response (Adamson et al., 1992; Lebowitz et al., 1995; Du et al., 1999a) . Taken together with the RIE results, these experiments supported a role for PRK activity and localization in the RhoB-mediated facets of the FTI response.
Discussion
The results of this study offer direct evidence that RhoB gain-of-function is a sufficient cause for FTI to bypass the action of farnesyl-independent oncoproteins in suppressing cell transformation. The work also strengthens the connection between RhoB and the FTI response by confirming its relevance in cells of epithelial origin, where actin-dependent polarity signals that impact transformation and proliferation processes likely occur through distinct mechanisms that are irrelevant in fibroblasts. Lastly, the results also support a role for interactions with the Rho effector protein PRK in mediating RhoB-dependent facets of the FTI response. PRK is a critical effector for the physiological function of RhoB in intracellular receptor trafficking, and our observations are consistent with a link between this function and the antiproliferative effects of RhoB.
K-ras-transformed RIE cells were highly susceptible to FTI treatment, lacking the relative 'resistance' observed by some laboratories in K-ras-transformed fibroblasts (compared to H-Ras-transformed fibroblasts). Although this resistance has been ascribed to the relatively higher avidity of K-Ras for FT, compared to H-Ras, our observations suggest that the 'resistance' phenomenon is a cell-type-specific property unrelated to the avidity of different Ras proteins for FT. Indeed, since the oncogenic activity of K-Ras remains intact when the protein is geranylgeranylated, as it is in FTItreated cells, the ability of FTI to suppress K-ras transformation is more readily explained by effects on non-Ras targets. Our observations rule in RhoB gain-offunction as a sufficient cause for explaining the suppression of K-ras transformation by FTI.
Another illustration that FTI can bypass geranylgeranylated oncoproteins to suppress transformation was provided by the demonstration that RIE/rac cells were susceptible to FTI. Rac1 is solely geranylgeranylated in cells, so FTI must act by indirectly blocking transformation; the induction of RhoB-GG and its ability to phenocopy FTI effects as in RIE/K-ras cells is consistent with a role for RhoB in the drug response. These observations have been corroborated and extended still further by the demonstration that FTI Figure 6 Effects of effector domain mutations on SRE-dependent transcriptional activation by RhoB-GG. Normalized luciferase activity was determined in cell extracts prepared 48 h after transfection of NIH3T3 cells with an SRE-luciferase reporter plasmid and vectors expressing no insert (vector), RhoB-GG, or the RhoB-GG effector domain mutant indicated (van Golen et al., 2002) . This result has clinical implications, because RhoC overexpression occurs in >90% of inflammatory breast cancers and ectopic RhoC recapitulates phenotype of these cancers (van Golen et al., 1999 (van Golen et al., , 2000a . FTI was shown to inhibit the anchorage-independent growth, motility and invasion of RhoC-transformed cells, and ectopic RhoB was sufficient to phenocopy these effects (van Golen et al., 2002) . Like Rac1, RhoC is solely geranylgeranylated in cells, so these observations strongly reinforce the notion that FTIs interfere with pro-oncogenic Rho signals by eliciting RhoB-GG.
We obtained genetic evidence supporting a role for PRK in RhoB-dependent facets of the FTI response. Effector mutations that abolished PRK interactions effectively limited the ability of RhoB-GG to suppress anchorage-independent growth or to activate SRE transcription. One implication is that antiproliferative effects of RhoB may involve downstream transcriptional events, a possibility supported by evidence that FTIinduced reversion in Rat1/ras cells requires derepression of the collagen Ia2 gene (Du et al., 1999b) . Another implication is that the antiproliferative and transcriptional effects of RhoB are derivative of the physiological function of RhoB in intracellular receptor trafficking, which also depends upon PRK interaction (Mellor et al., 1998; Gampel et al., 1999; Flynn et al., 2000) . Experiments in a fibroblast model system supported a role for PRK in the FTI response. Elevation of PRK relieved the serum deprival requirement for FTI-induced apoptosis, in a manner dependent on the integrity of the PRK kinase domain, whereas elevation of myristylated PRK (which does not require Rho interaction for membrane localization) blocked FTI-induced apoptosis. The latter observation argued that PRK localization is important: the ability of PRK to block FTI-induced apoptosis when PRK was localized to membranes in a Rho-independent fashion argued that movement away from membrane-associated sites was integral to its participation in the FTI response. This interpretation of the results is consistent with the evidence that FTI both elevates and relocalizes RhoB in cells (Lebowitz et al., 1995) . Although PRK2 has been reported to be cleaved and activated by caspases during apoptosis (Cryns et al., 1997; Takahashi et al., 1998) , we did not observe this event. A link between PRK and FTIinduced apoptosis is potentially interesting based on reports of the ability of PRK to complex with RhoB and the Akt-regulatory enzyme PDK1 in certain epithelial and endothelial cells (Balendran et al., 1999; Flynn et al., 2000) (L. Benjamin, pers. comm.), the potential of cleaved PRK to modulate Akt activity (Koh et al., 2000) , and the ability of RhoB-GG to phenocopy the inhibition of Akt activity by FTI in epithelial and endothelial cells (L Benjamin, pers. comm.). Further investigations may shed additional light on the signaling mechanisms that relate PRK to the RhoB-dependent aspects of the FTI response.
The most informative mutations in the RhoB effector domain that were tested in this study were the F39L and F39V mutations, which differentially distinguish PRK interaction (Table 1) . RhoB-GG-mediated growth suppression was maintained by F39L mutation, which supports PRK interactions, but was abolished by F39V mutation, which abolishes PRK interaction. Notably, the same mutations made in the pro-oncogenic RhoA protein abolish its cell-transforming activity with Raf Nterminal truncates (Sahai et al., 1998; Zohar et al., 1998) . Thus, F39L mutation suppresses the transforming activity of RhoA, whereas F39V supports this activity. Taken together, these results suggest that the antioncogenic function of RhoB is based on its competition with RhoA for PRK binding, insofar as RhoB must bind PRK to suppress transformation and RhoA must bind PRK to drive transformation. The induction and relocalization of RhoB-GG caused by FTI treatment may sequester PRK, inhibiting its ability to bind RhoA and mediate pro-oncogenic signals. This model is consistent with the Rat1/ras results, which suggested that PRK localization or movement is important to the FTI response. It is also consistent with the evidence that FTI elicits a relocalization of RhoB (i.e. RhoB-GG) in drug-treated cells (Lebowitz et al., 1995) (H. Mellor, pers. comm.). As mentioned above, Ras transformation requires pro-oncogenic Rho signals. Therefore, by eliciting RhoB-GG, FTI may interfere with pro-oncogenic Rho signals to block Ras transformation (see Figure 8) . This model can also offer an explanation for how RhoB-GG mediates the antagonistic effects of FTI on RhoC transformation (van Golen Figure 8 Model. RhoB is a short-lived protein with a rapid synthesis rate. FTI blocks the ability to replace RhoB-F, which is turned over. Relative levels of the geranylgeranylated RhoB isoform increase as the farnesylated isoform is depleted (Figure 1a ). This event is also associated with a change in subcellular localization (Lebowitz et al., 1995) . Elevation and movement of the antioncogenic RhoB protein may lead to competition for regulators or effectors that normally interact with the pro-oncogenic RhoA or RhoC proteins, such as PRK. Such competition may attenuate prooncogenic Rho signals owing to sequesteration of certain effectors needed for cell transformation. In the model, RhoB accesses redundant effector molecules that can drive actin stress fiber formation, separate from effectors that may be needed for transformation et al., 2002) , through the ability of RhoB-GG to compete with RhoC for PRK interactions. The notion that RhoB antioncogenic activity is based on competition for effectors or nucleotide exchange factors (GEFs) of pro-oncogenic Rho proteins is consistent with structural considerations and offers considerable explanative and predictive power. The utility of FTI to interfere with Rho signaling through these mechanisms may find clinical utility in novel disease settings that involve Rho, including inflammatory breast cancer, melanoma, and age-associated blindness as we have suggested (Prendergast, 2000b; Prendergast and Rane, 2001) .
